newscontact us

News

CESCA CLI FEASIBILITY STUDY PUBLISHED IN PEER-REVIEWED JOURNAL

Rancho Cordova, CA, March 20, 2017 — Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the publication in a peer reviewed journal of data from its Critical Limb Ischemia (CLI) feasibility study utilizing the Company’s innovative point-of-care technology. The report was published in the …

CESCA THERAPEUTICS HIGHLIGHTS PROMISING DATA FOR THE TREATMENT OF CHRONIC NON-HEALING ULCERS

RANCHO CORDOVA, CA, March 15, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced encouraging data from a study evaluating the use of autologous platelet rich plasma(PRP) for the treatment of chronic non-healing ulcers…(more)  

CESCA THERAPEUTICS ANNOUNCES CLOSING OF $5 MILLION REVOLVING LINE OF CREDIT

RANCHO CORDOVA, CA, March 13, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced that it has closed a revolving line of credit (“RLOC”) with Boyalife Investment Fund II, Inc. The non-collaterized RLOC is for a term of five years and is generally …

CESCA THERAPEUTICS STRENGTHENS LEADERSHIP TEAM AND BOARD OF DIRECTORS

RANCHO CORDOVA, CA, February 28, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced that it has appointed Ms. Vivian Liu as its Chief Operating Officer and elected Dr. Russell Medford to its board of directors…(more)

CESCA THERAPEUTICS REPORTS SECOND QUARTER FISCAL 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Rancho Cordova, CA, February 13, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapies, today reported second quarter financial results for 2017 and provided an update to investors…(more)

CESCA THERAPEUTICS TO ANNOUNCE SECOND QUARTER FISCAL 2017 RESULTS ON FEBRUARY 13, 2017

Rancho Cordova, CA, February 9, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and point-of-care autologous cell- based therapies, announced today it will report financial results for the fiscal second quarter ended December 31, 2016, on Monday, February 13, 2017…(more)

CESCA THERAPEUTICS APPOINTS DR. JOSEPH THOMIS TO ITS BOARD OF DIRECTORS

Rancho Cordova, CA, January 17, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, today announced that Dr. Joseph Thomis will join the Company’s Board of Directors…(more)

CESCA ANNOUNCES FDA APPROVAL OF IDE SUPPLEMENT FOR PHASE III CLINICAL TRIAL

Rancho Cordova, CA, January 5, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapies, announced today that the Company received approval from the U.S. Food and Drug Administration (FDA) for significant revisions to the Company’s pivotal study for treatment of Critical Limb Ischemia (CLI). The …

CESCA THERAPEUTICS TO PRESENT AT THE 9TH ANNUAL BIOTECH SHOWCASE

Rancho Cordova, CA, January 3, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, today announced that it is scheduled to present at the 9th Annual Biotech Showcase, being held on January 9-11, 2017 at the Hilton San Francisco Union Square in San Francisco, CA…(more)

CESCA SUBMITS IDE SUPPLEMENT FOR CLI PIVOTAL TRIAL

Rancho Cordova, CA, December 5, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, today announced that on November 21, 2016 the Company has submitted an Investigational Device Exemption (IDE) Supplement to the U.S. Food and Drug Administration (FDA) for its previously approved pivotal trial. …

CESCA THERAPEUTICS TO PRESENT AT THE 9TH ANNUAL LD MICRO MAIN EVENT

Rancho Cordova, CA, December 2, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, today announced that it is scheduled to present at the 9th Annual LD Micro Main Event, being held on December 6-8, 2016 at the Luxe Sunset Boulevard Hotel in Los Angeles, …

CESCA THERAPEUTICS REPORTS FIRST QUARTER FISCAL 2017 RESULTS AND PROVIDES BUSINESS UPDATE

Management to Hold Conference Call Today at 2:00pm Pacific (5:00pm Eastern) Rancho Cordova, CA, November 17, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, today reported first quarter financial results for 2017 and provided an update to investors.(more)

CESCA THERAPEUTICS TO ANNOUNCE FIRST QUARTER FISCAL 2017 RESULTS ON NOVEMBER 17, 2016

Rancho Cordova, CA, November 16, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, announced today it will report financial results for the fiscal first quarter ended September 30, 2016, on Thursday, November 17, 2016. (more)

CESCA THERAPEUTICS GRANTED THIRD U.S. PATENT RELATING TO ITS PROPRIETARY SURGWERKSTM PLATFORM

Rancho Cordova, CA, October 18, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the third of a family of patent applications related to its proprietary methods for the treatment of ischemic cardiovascular disorders, such as …

CESCA THERAPEUTICS TO PRESENT & EXHIBIT AT THE ISCT NORTH AMERICA 2016 REGIONAL MEETING

Rancho Cordova, CA, September 27, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Dalip Sethi, Ph.D., Director of Clinical Research, will be presenting at the 2016 International Society for Cellular Therapy (ISCT) North America Regional Meeting, to be held from September 30 to October 2, 2016 at …

CESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL 2016 YEAR END RESULTS

Management to Hold Conference Call Today at 2:00pm Pacific (5:00pm Eastern) Rancho Cordova, CA, September 20, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today reported fourth quarter and full year financial results for fiscal 2016 and provided an update to investors… (more)

CESCA THERAPEUTICS GRANTED TWO PATENTS FOR RAPID INFUSION OF AUTOLOGOUS BONE MARROW DERIVED STEM CELLS

Technology Fundamental to Cesca’s Proprietary SurgWerks™ Platform for CLI and AMI Rancho Cordova, CA, September 19, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the first two of a family of patent applications related to …

CESCA THERAPEUTICS TO REPORT FISCAL FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE

Rancho Cordova, CA, September 16, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal fourth quarter and full year ended June 30, 2016 and provide a business update to investors on Tuesday, September 20, 2016… (more)

Cesca Therapeutics to Present at the 18th Annual Rodman & Renshaw ® Global Investment Conference

RANCHO CORDOVA, CA, September 8, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Michael Bruch, Cesca’s Chief Financial Officer, and Dalip Sethi, Ph.D., Director of Clinical Research will present at the Rodman & Renshaw®18th Annual Global Investment Conference, being held at The Lotte New York Palace Hotel …

CESCA THERAPEUTICS ANNOUNCES CONVERSION OF $12.5 MILLION IN SENIOR SECURED DEBT TO EQUITY

RANCHO CORDOVA, CA, August 24, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has converted a senior secured three year convertible debenture of $12.5 million of principal and $8.25 million of interest to 6,102,941 shares of its common stock. The conversion was effected in accordance …

CESCA THERAPEUTICS ANNOUNCES PRICING OF $2.5 MILLION REGISTERED DIRECT OFFERING

Rancho Cordova, CA, – August 4, 2016 – Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it has entered into definitive subscription agreements with institutional investors to purchase 600,000 shares of common stock at a purchase price per share of $4.10 for gross proceeds of approximately $2.5 million in a …

Cesca Therapeutics announces promising results from 40-month follow-up of patient enrolled in critical limb ischemia feasibility study

Rancho Cordova, CA, – August 3, 2016 – Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced 40-month follow-up results for a number of patients that participated in the Company’s earlier feasibility study using Cesca’s proprietary SurgWerks™ system for the treatment of late stage, “no option” critical limb ischemia (CLI). More…

Cesca therapeutics announces publication of results on use of its technology for treatment of non-union fracture

Data from Pilot Study Shows Promising Results for Bone Regeneration RANCHO CORDOVA, CA, August 2, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that data for its proprietary technology was published in the Herald Scholarly Open Access (HSOA) Journal of Stem Cells Research, Development and Therapy, which is …

Cesca Therapeutics provides update on FDA review of investigational device exemption supplement for Surgwerks™ CLI pivotal trial

FDA Approves Commencement of Phase III Pivotal Trial as Amended Requires Additional Validation of TcPO2 as a Surrogate to Support Subsequent PMA Approval RANCHO CORDOVA, CA, August 1, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, is today updating investors on the status of the U.S. Food and Drug Administration’s …

Cesca therapeutics appoints mark bagnall to its board of directors

RANCHO CORDOVA, CA, June 20, 2016 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Mark Bagnall has been appointed to the Company’s Board of Directors, effective July 1, 2016. More.

CESCA THERAPEUTICS TO PRESENT AT THE LD MICRO INVITATIONAL CONFERENCE

Rancho Cordova, CA, June 6, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Michael Bruch, the Company’s Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the LD Micro Invitational, being held June 7 – 9, 2016 …

CESCA THERAPEUTICS SUBMITS INVESTIGATIONAL DEVICE EXEMPTION SUPPLEMENT FOR SURGWERKS™ CLI PIVOTAL TRIAL

Rancho Cordova, CA, June 1, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has submitted an Investigational Device Exemption (IDE) Supplement to the U.S. Food and Drug Administration (FDA) for its previously approved pivotal trial for the treatment of patients with critical limb ischemia (CLI), …

CESCA THERAPEUTICS TO EXHIBIT AT THE 2016 INTERNATIONAL SOCIETY FOR CELLULAR THERAPY ANNUAL MEETING

Rancho Cordova, CA, May 24, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 2016 International Society for Cellular Therapy (ISCT) Annual Meeting in Booth B06 on May 25-28, 2016 at the Suntec Convention and Exhibition Center in Suntec City, Singapore. …

CESCA THERAPEUTICS TO REVIEW RECENT CORPORATE MILESTONES AT THE MARCUM MICROCAP CONFERENCE

Rancho Cordova, CA, May 20, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company’s management team including, Mr. Robin Stracey, Chief Executive Officer, Mr. Michael Bruch, Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the Marcum …

CESCA THERAPEUTICS ANNOUNCES PUBLICATION OF A CASE REPORT ON USE OF ITS TECHNOLOGY FOR TREATMENT OF ACUTE MYOCARDIAL INFARCTION

RANCHO CORDOVA, CA, May 19, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced publication of data from a pilot study utilizing the company’s innovative technology for treatment of Acute Myocardial Infarction. The report was published in the “International Journal of the Cardiovascular Academy”, currently online. More.

Cesca Therapeutics Reports Results from Compassionate use of SurgWerks Procedure on CLI Patients

Rancho Cordova, CA, May 11, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced the results of six late-stage critical limb ischemia (CLI) patients treated with its SurgWerks™-CLI system on a compassionate use basis.  More.

CESCA THERAPEUTICS TO REPORT THIRD QUARTER FISCAL 2016 RESULTS ON MAY 12, 2016

Rancho Cordova, CA, May 9, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal second quarter ended March 31, 2016 and provide a status update to investors on Thursday, May 12, 2016.   Read More.

WALL STREET TRANSCRIPT INTERVIEW WITH CESCA’S CEO ROBIN STRACEY, MARCH, 2016

Cesca Therapeutics’ CEO Robin Stracey recently spoke with the Wall Street Transcript about the Company’s current business and plans for the future. Follow link to entire article:   WallStreetTranscript_MAR2016

Cesca Therapeutics T o Present A Poster At The 2016 Annual Meeting Of The European Society For Blood And Bone Marrow Transplantation

Rancho Cordova, California – March 31, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will present a poster titled “Volume Reduction and RBC Depletion of Apheresis Products for Transplant” at the 42nd Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT) …

cesca therapeutics’ indian subsidiary expands cord blood banking services to additional hospitals in the fortis healthcare network

RANCHO CORDOVA, Calif., March 30, 2016 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that its wholly-owned subsidiary in India, TotiPotentRX, has expanded its private cord blood banking services into several hospitals within the Fortis Healthcare network in South and West India. Read More.      

Cesca Therapeutics Appoints Vascular Surgery Expert Lars Norgren, M.D., Ph.D. to its Clinical Advisory Board

RANCHO CORDOVA, Calif., March 23, 2016 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Dr. Lars Norgren, MD, Ph.D has joined its Clinical Advisory Board. Having authored over 500 research publications, Dr. Norgren is an internationally renowned authority on peripheral arterial disease (PAD) and vascular and endovascular surgery. Read …

Cesca Therapeutics to Present at the ARM 4th annual cell and gene therapy investor day

Cesca Therapeutics to Present at the ARM 4th Annual Cell & Gene Therapy Investor Day Rancho Cordova, California – March 16, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Mike Bruch, Cesca Therapeutics’ Chief Financial Officer, will present at the Alliance for Regenerative Medicine’s 4th Annual Cell …

Cesca Therapeutics Appoints Dr. Xiaochun Xu, Chairman and CEO of Boyalife Group, to Board of Directors

RANCHO CORDOVA, Calif., March 10, 2016 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Dr Xiaochun Xu (44) has been appointed to the Company’s Board of Directors. Read More

CESCA THERAPEUTICS REPORTS SECOND QUARTER FISCAL 2016 RESULTS AND PROVIDES A STATUS UPDATE TO INVESTORS

RANCHO CORDOVA, CA – February 16, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL, the “Company”), an autologous cell-based regenerative medicine company, today reported financial results for the second quarter of fiscal 2016 and provided an update to investors. Read More

Cesca Therapeutics to Announce Second Quarter Fiscal 2016 Results on February 16

Rancho Cordova, CA, February 11, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal second quarter ended December 31, 2015 and provide a status update to investors on Tuesday, February 16, 2016. More details.

Texas Stem Cell Enters into an Agreement with Cesca Therapeutics for Use of AutoXpress Technology for Cord Blood Processing

RANCHO CORDOVA, Calif and Houston, Texas – February 09, 2016 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Texas Stem Cell has committed to utilizing Cesca’s AutoXpress® AXP technology for its cord blood banking business. Read More.

Cesca Announces $15 Million Strategic Investment from Boyalife Group.

RANCHO CORDOVA, Calif., February 2, 2016 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that affiliates of Boyalife Group have agreed to invest $15.0 million in the Company (the “Boyalife Financing”), enabling the Company to repay currently outstanding senior secured convertible debentures and retire associated Series B Warrants. The …

CESCA THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE IN SAN FRANCISCO ON JANUARY 13, 2016

RANCHO CORDOVA, Calif., January 7, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company announced today that the Company will present at the Biotech Showcase™ 2016 on Wednesday, January 13th at 11:30 AM PT (2:30 PM ET).  Biotech Showcase is an investor and partnering conference devoted to providing private and public …

Cesca Therapeutics Sponsors First Symposium on Haploidentical Stem Cell Transplantation in India

RANCHO CORDOVA, Calif –January 5, 2016 – Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it is hosting the first annual Symposium on Haploidentical Stem Cell Transplantation in Delhi, India on January 7, 2016. The symposium will bring together National and International experts in the field of pediatrics and hematology/oncology …

CESCA RECEIVES APPROVAL FOR MEDICARE COVERAGE

IDE Study Protocol Critical Limb Ischemia by SurgWerksTM-CLI Kit and VXP System (“CLIRST III”) Meets Requirements of Center for Medicare and Medicaid Services for Reimbursement RANCHO CORDOVA, Calif., December 2, 2015 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it has received approval for Medicare coverage for the …

CESCA THERAPEUTICS TO PRESENT AT 2015 LD MICRO MAIN EVENT

RANCHO CORDOVA, Calif – November 20, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, announced today that it will be presenting and meeting with investors at the 8th annual LD Micro Main Event on Wednesday, December 2 in Bel Air, California at the Luxe Sunset Hotel. Read More

CESCA THERAPEUTICS REPORTS FIRST QUARTER FISCAL YEAR 2016 FINANCIAL RESULTS

Updates Investors on Financing Initiatives and the Status of Clinical Programs Management will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern) RANCHO CORDOVA, CA – November 16, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the first quarter of fiscal 2016 and provided …

CESCA THERAPEUTICS TO PRESENT AT 2015 WORLD ALLIANCE FORUM IN SAN FRANCISCO

Regenerative Medicine: Let’s Talk Business! RANCHO CORDOVA, Calif – November 12, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Robin Stracey, Chief Executive Officer and Dalip Sethi, Ph.D., Senior Clinical Scientist of Cesca Therapeutics will be presenting at the World Alliance Forum in San Francisco (WAFSF) on …

CESCA THERAPEUTICS TO ANNOUNCE FIRST QUARTER FISCAL 2016 RESULTS ON NOVEMBER 16, 2015

Rancho Cordova, CA, November 10, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal first quarter ended September 30, 2015, on Monday, November 16, 2015. Read More

CLI DATA FROM CESCA™S PHASE I/PHASE II AND FEASIBILITY STUDIES TO BE PRESENTED AT THE AMERICAN HEART ASSOCIATION-SCIENTIFIC SESSIONS CONFERENCE BY RICHARD POWELL, M.D.

RANCHO CORDOVA, Calif – November 9, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Dr. Richard Powell, MD is presenting Cesca’s feasibility data on critical limb ischemia (CLI) at the American Heart Association-Scientific Sessions Conference in Orlando, Florida. The data presented will summarize results from two cardiovascular …

Miltenyi Biotec and Cesca Therapeutics™ Subsidiary TotipotentRX Announce Multi-Year Commercial Agreement for Bone Marrow Transplantation

RANCHO CORDOVA, Calif – October 28, 2015 – Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that its subsidiary, TotipotentRX, has signed a multi-year distribution agreement with Miltenyi Biotec GmbH (Germany) for clinical product sales throughout India. Read More

MICHAEL BRUCH APPOINTED CHIEF FINANCIAL OFFICER OF CESCA THERAPEUTICS

Rancho Cordova, CA, October 26, 2015 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Board of Directors had appointed Michael Bruch Chief Financial Officer. Read More

Cesca Therapeutics to Present Progress on its CellWerks™ Product Pipeline at the AABB Conference in Anaheim, California, October 24-27

RANCHO CORDOVA, Calif – October 23, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it will be presenting at the annual American Association of Blood Banks conference in Anaheim, California October 24-27. The poster, entitled “Volume Reduction and RBC Depletion of Apheresis Products for Cryopreservation,” will report …

Cesca Therapeutics Clinical Laboratory Successfully Facilitates Haploidentical Bone Marrow Transplant Procedure on Unique Pediatric Patient in Need

RANCHO CORDOVA, Calif – October 19, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that its Clinical GMP Cell Processing Laboratory “TotipotentRX Centre for Cellular Medicine” located at Fortis Memorial Research Institute (FMRI), New Delhi, N.C.R., India, performed a specialized T-cell preparation procedure designed for a unique haploidentical …

St. Jude Children’s Research Hospital and Cesca Therapeutics Enter into Collaboration Agreement Targeting Bone Marrow Transplantation

RANCHO CORDOVA, Calif – October 1, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it has entered into a collaboration agreement with St. Jude Children’s Research Hospital, Memphis, Tennessee. Read More

CESCA THERAPEUTICS INVITED TO PRESENT AT AEGIS CAPITAL GROWTH CONFERENCE, AND THE STEM CELL MEETING ON THE MESA CONFERENCE

RANCHO CORDOVA, Calif., October 1, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company announced today that the Company will present at the 2015 Aegis Capital Growth Conference, and the 2015 Stem Cell Meeting on the Mesa on Thursday, October 8, 2015. Read More

Ken Harris to Step Down as President of Cesca Therapeutics

Will serve as an Advisor to the Company for up to 18 months RANCHO CORDOVA, Calif – September 28, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Kenneth L. Harris is stepping down as President of the Company and from the Board of Directors in the U.S., …

CESCA THERAPEUTICS REPORTS FISCAL YEAR 2015 RESULTS

Notes Significant Advances in Leading Clinical Programs; Management will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern) RANCHO CORDOVA, CA – September 17, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the fourth quarter and year ended fiscal 2015 and provided an update …

Cesca Therapeutics Enters into Collaborative Agreement with Center for Immune Cell Therapies at Memorial Sloan Kettering Cancer Center

RANCHO CORDOVA, Calif – September 16, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it has entered into a collaboration agreement with Center for Immune Cell Therapies (CICT) at Memorial Sloan Kettering Cancer Center focused on the CellWerksTM portfolio of devices for intra-laboratory stem cell purification applications.  …

Cesca Therapeutics Announces Restructuring Initiative

RANCHO CORDOVA, CA September 15, 2015, Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it has undertaken a restructuring initiative geared towards reducing costs associated with its traditional cord blood banking business and further aligning available resources behind the Company’s high impact clinical programs, including the Phase III pivotal …

CESCA THERAPEUTICS TO PRESENT AT THE RODMAN & RENSHAW® 17th ANNUAL GLOBAL INVESTMENT CONFERENCE

Rancho Cordova, CA, September 10, 2015 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, today announced that Ken Harris, President of Cesca Therapeutics, will present at the Rodman & Renshaw® Annual Global Investment Conference, being held at the St. Regis Hotel in New York. The presentation will take place today, September …

Cesca Therapeutics to Announce Fourth Quarter & Fiscal 2015 Year End Results on September 17, 2015

Rancho Cordova, CA, September 10, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal fourth quarter and year ended June 30, 2015, on Thursday, September 17, 2015. Read More

Cesca Therapeutics Secures $15 Million Financing from Institutional Life Sciences Fund

Financing Paves Way Toward Achievement of Major Clinical Milestones RANCHO CORDOVA, Calif – September 1, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced the signing and initial closing of a definitive agreement on August 31, 2015, to raise $15 million in senior secured convertible debentures and warrants from …

CESCA THERAPEUTICS ANNOUNCES COMPLIANCE WITH NASDAQ STOCK MARKET UNDER LISTING RULE 5250(C)(1)

RANCHO CORDOVA, Calif – June 25, 2015 – Cesca Therapeutics, Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has received a letter from the office of Nasdaq Listings Qualifications dated June 24, 2015, indicating that the Company complies with Nasdaq Listing Rule 5250(c)(1) because the Company has filed its Forms …

CESCA THERAPEUTICS REPORTS THIRD QUARTER FISCAL 2015 RESULTS

Company receives US FDA approval for its IDE Submission to the FDA for a Phase III Pivotal Clinical Trial for the Treatment of Patients with Critical Limb Ischemia (CLI) Management will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern) RANCHO CORDOVA, CA – June 23, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an …

Cesca Therapeutics Announces Issuance of New U.S. Patent

RANCHO CORDOVA, California – June 23, 2015 – Cesca Therapeutics, Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced the issuance of U.S. Patent No. 9,050,422 by the U.S. Patent and Trademark Office.  The patent for “Stem and Progenitor Cell Compositions Recovered from Bone Marrow or Cord Blood” is a divisional for U.S. Patent …

CESCA THERAPEUTICS TO ANNOUNCE THIRD QUARTER FISCAL 2015 RESULTS ON JUNE 23, 2015

Rancho Cordova, CA, June 17, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal third quarter ended March 31, 2015, on Tuesday, June 23, 2015. Read More

CESCA THERAPEUTICS RECEIVES FDA IDE APPROVAL FOR U.S. PIVOTAL CLINICAL TRIAL IN CRITICAL LIMB ISCHEMIA

Rancho Cordova, CA, June 16, 2015 – Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for an Investigational Device Exemption (IDE) for the Company’s pivotal clinical trial, named the CLIRST III trial, to evaluate Cesca’s SurgWerks™-CLI and VXP System …

CESCA THERAPEUTICS BOARD OF DIRECTORS APPOINT ROBIN C. STRACEY AS CHIEF EXECUTIVE OFFICER

Rancho Cordova, CA, June 12, 2015 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, announced today the appointment of Robin C. Stracey as Chief Executive Officer. Read More

CESCA THERAPEUTICS ANNOUNCES MARCUM LLP AS THE COMPANY™S NEW INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Rancho Cordova, CA, June 1, 2015 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has appointed Marcum LLP as its independent registered public accounting firm. Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States. Read More

Cesca Therapeutics to Present at the 2015 Marcum Microcap Conference

RANCHO CORDOVA, Calif – May 21, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced the Company will be presenting at the 2015 Marcum Microcap Conference being held on May 27-28, 2015 at The Grand Hyatt New York. Kenneth L. Harris, President and Head of the Company’s clinical programs, …

Cesca Therapeutics Receives IEC/IRB Approval to Initiate Acute Myocardial Infarction Study

AMIRST II Feasibility (Phase II) study to evaluate the SurgWerks-AMI and VXP System in patients with low LVEF following a heart attack RANCHO CORDOVA, Calif – May 20, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it has received Institutional Ethics Committee (IEC) approval to initiate the …

Cesca Therapeutics Submits U.S. Pivotal IDE Amendment Application for Late Stage Critical Limb Ischemia (CLI)

RANCHO CORDOVA, Calif – May 13, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced it has submitted its amendment to the investigational device exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for a U.S. pivotal multicenter study of the Company’s SurgWerks™-CLI and VXP System (SurgWerks-CLI) …

Cesca Therapeutics Announces Change in Corporate Auditors

RANCHO CORDOVA, California – May 12, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it has begun a search for a new accounting firm. Ernst & Young LLP (E&Y) has resigned as the Company’s independent registered public accounting firm and E&Y’s resignation has been accepted by the …

Cesca Therapeutics Announces Changes in Management

RANCHO CORDOVA, Calif., May 4, 2015 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Dan T. Bessey has resigned as Chief Financial Officer of Cesca Therapeutics effective May 9, 2015. Mr. Bessey has accepted a position as Chief Financial Officer of Hawaiian Telcom, a provider of integrated …

Cesca Therapeutics Management Provides Update on Clinical Trials for Critical Limb Ischemia (CLI) and Acute Myocardial Infarction (AMI)

RANCHO CORDOVA, Calif., April 10, 2015 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced a corporate update on Cesca’s clinical trial program in CLI and AMI.   Critical Limb Ischemia As previously announced in early January, the Company received a letter from the U.S. Food and Drug Administration (“FDA”) …

Cesca to Present at the 2nd Annual Growth Capital Expo

RANCHO CORDOVA, Calif., April 8, 2015 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced the Company will be presenting at the 2nd Annual Growth Capital Expo being held on April 12-14, 2015 at Caesars Palace in Las Vegas, NV. Read More

CESCA THERAPEUTICS TO PRESENT AT 3RD ANNUAL REGEN MED INVESTOR DAY

Rancho Cordova, CA, March 19, 2015 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, announced today it will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 in New York City. Read More

CESCA THERAPEUTICS RECEIVES NOTICE OF NON-COMPLIANCE WITH NASDAQ LISTING RULE

Rancho Cordova, CA, February 27, 2015 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, announced today that the Company received a letter from Nasdaq indicating that the Company had become non-compliant with the Nasdaq Listing Rule 5250(c)(1) requiring the Company to timely file its December 31, 2014 quarterly report with the …

CESCA THERAPEUTICS REPORTS SECOND QUARTER FISCAL 2015 RESULTS

Company to Provide an Update on the Status of its IDE Submission to the FDA for a Phase III Pivotal Clinical Trial for the Treatment of Patients with Critical Limb Ischemia Management will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern) RANCHO CORDOVA – February 12, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), …

Cesca Therapeutics Announces Approval of its MarrowXpress(TM) System in India

RANCHO CORDOVA, Calif., February 11, 2015 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has received approval from the India Drug Controller General (“DCGI”) for the import and commercialization of its MarrowXpressTM (“MXPTM”) System in India. Read More

CESCA THERAPEUTICS TO ANNOUNCE SECOND QUARTER FISCAL 2015 RESULTS ON FEBRUARY 12, 2015

Rancho Cordova, CA, February 11, 2015 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal second quarter ended December 31, 2014, on Thursday, February 12, 2015. Read More

CESCA THERAPEUTICS TO PRESENT AT 17TH ANNUAL BIO CEO & INVESTOR CONFERENCE

Rancho Cordova, CA, February 9, 2015 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, announced today that the Company will be presenting at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 …

CESCA THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE IN SAN FRANCISCO ON JANUARY 13, 2015

RANCHO CORDOVA, Calif., January 8, 2015 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company announced today that the Company will present at the Biotech Showcase™ 2015 on Tuesday, January 13th at 10:00 AM PT (1:00 PM ET). Read More

Cesca Receives Feedback from the FDA on its Pivotal Investigational Device Exemption (IDE) Application for Treating Critical Limb Ischemia (CLI)

RANCHO CORDOVA, Calif., January 2, 2015– Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that it has received a letter from the U.S. Food and Drug Administration responding to the Company’s investigational device exemption (IDE) application for its pivotal CLIRST III clinical trial.  The IDE application, filed on November 20, …

CESCA THERAPEUTICS INVITED TO PRESENT AT LD MICRO CONFERENCE AND THE WORLD STEM CELL SUMMIT

RANCHO CORDOVA, Calif., November 26, 2014 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company announced today that the Company will present at the LD Micro Conference on Tuesday, December 2nd and at the World Stem Cell Summit on Wednesday, December 3rd. Read More

Cesca Therapeutics Announces Filing of U.S. Pivotal IDE Application for No-Option Critical Limb Ischemia (™CLI™)

CLIRST III study to evaluate the SURGWERKS-CLI and VXP System in Patients with CLI RANCHO CORDOVA, Calif – November 20, 2014 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company developing proprietary devices and methods for cardiovascular, orthopedic and hematological/oncological procedures, today announced it has submitted an investigational device exemption (“IDE”) application …

CESCA THERAPEUTICS REPORTS FIRST QUARTER FISCAL 2015 RESULTS

Company Completes its Pivotal Clinical Trial Protocol for Treating Patients with Critical Limb Ischemia for Submission to the FDA Management will hold a conference call today at 2:00pm Pacific (5:00pm Eastern) to review the first quarter fiscal 2015 financial results  RANCHO CORDOVA – November 13, 2014 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based …

CESCA THERAPEUTICS TO ANNOUNCE FIRST QUARTER FISCAL 2015 RESULTS ON NOVEMBER 13, 2014

Rancho Cordova, CA, November 12, 2014 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal first quarter ended September 30, 2014, on Thursday, November 13, 2014. Read More

Cesca Therapeutics Announces Change in Executive Leadership

Cesca to Search for Industry Veteran to Advance its Clinical and Commercialization Strategy Robin C. Stracey, Cesca Therapeutics’ Board Member to Serve as Interim CEO RANCHO CORDOVA, Calif., October 29, 2014 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced it intends to embark on a nationwide search for a …

CESCA THERAPEUTICS ANNOUNCES AGREEMENT WITH NEW YORK UPSTATE CORD BLOOD BANK

Cesca to Provide Storage, Processing and Consumable Platform RANCHO CORDOVA, Calif., and SYRACUSE, NY, October 13, 2014 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has successfully secured a contract to provide its cell storage, processing and consumables platform to Upstate Medical University’s, Upstate Cord Blood …

CESCA THERAPEUTICS TO PRESENT AT STEM CELL MEETING ON THE MESA

RANCHO CORDOVA, Calif., October 6, 2014 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company announced today that Kenneth Harris the Company’s President will present at the 4th Annual Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA. Organized by the Alliance for Regenerative Medicine (ARM), …

CESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL FISCAL 2014 RESULTS

Company Completes Year of Transformation, Makes Regulatory Advances in Clinical Programs RANCHO CORDOVA – September 29, 2014 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the fourth quarter and year-ended fiscal 2014. “We have made significant advancements in the development of our cell therapy clinical program …

Cesca Therapeutics Reschedules Fourth Quarter and Full Year Earnings Release

RANCHO CORDOVA, Calif., September 25, 2014 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, announced today that it is rescheduling its previously announced earnings conference call for fiscal year end 2014. The Company intends to reschedule the conference call to provide additional time necessary to finalize its accounting for income taxes …

CESCA THERAPEUTICS TO ANNOUNCE FOURTH QUARTER AND FISCAL 2014 YEAR END RESULTS ON SEPTEMBER 25, 2014

Rancho Cordova, CA, September 23, 2014 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal fourth quarter and year ended June 30, 2014, on Thursday, September 25, 2014.  Company’s Conference Call and Webcast Management will host a conference call Thursday, September 25, …

Cesca Therapeutics to Present at Aegis Healthcare & Technology Conference

RANCHO CORDOVA, Calif., September 10, 2014 – Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, announced today it will present at the Aegis Healthcare & Technology Conference on Friday, September 12, 2014 at the Encore at the Wynn Las Vegas. The Company’s presentation by Matthew Plavan, the Company’s Chief Executive Officer is …

CESCA THERAPEUTICS TO PRESENT AT THE RODMAN & RENSHAW® 16th ANNUAL GLOBAL INVESTMENT CONFERENCE

Rancho Cordova, CA, September 4, 2014 — Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, today announced that Matthew Plavan, Chief Executive Officer of Cesca, will present at the Rodman & Renshaw® Annual Global Investment Conference, being held at the New York Palace Hotel in New York. The presentation will take place …

Cesca Therapeutics Advocates Benefits of Cell Therapy to the Centers for Medicare and Medicaid Services

Cesca Therapeutics invited by the Alliance for Regenerative Medicine to present case study to CMS for treating Critical Limb Ischemia with SurgWerks® – CLI Cell Therapy Rancho Cordova, CA, August 27, 2014 — Cesca Therapeutics Inc. (Nasdaq: KOOL) an autologous cell-based regenerative medicine company today announced the presentation to the Centers for Medicare and Medicaid …

CESCA THERAPEUTICS AND FORTIS HEALTHCARE ANNOUNCE MASTER COLLABORATION AGREEMENT

Cesca Therapeutics Expands Scope of Services as Exclusive Provider of Regenerative Medicine to the Largest Private Hospital in Asia RANCHO CORDOVA, Calif., and GURGAON, India August 5, 2014– Cesca Therapeutics, an autologous cell-based regenerative medicine company, and Fortis Healthcare Limited, India’s fastest growing hospital network, announced a master collaboration agreement that extends their important existing …

CESCA Management Provides Regulatory Update on its Proposed U.S. Pivotal Critical Limb Ischemia Clinical Trial

RANCHO CORDOVA, Calif., July 8, 2014 — Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, announced today that it recently participated in a pre-submission IDE (Investigational Device Exemption) teleconference with the Food and Drug Administration’s (“FDA”) Center for Biologics Evaluation and Research to discuss the Company’s proposed pivotal clinical trial design for …